Abbott On Track To Reach U.S. Drug-Eluting Stent Market By Late 2007
This article was originally published in The Pink Sheet Daily
Company earns FDA green light for planned 1,670-patient ZOMAXX II randomized trial of ZoMaxx drug-eluting stent. Study will compare ABT-578-eluting TriMaxx-platform stent to Boston Scientific's Taxus.
You may also be interested in...
Simplify’s total disc replacement complements NuVasive’s C360 line of cervical repair surgery devices, addressing a market that could eventually be worth $2.6bn.
The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.
Mickelsen, an electrophysiologist at the University of Iowa, recently joined the rapidly growing San Diego-area company as Chief Translational Science Officer and is helping to guide the company’s development of novel electrophysiology therapies to treat cardiac arrhythmias.